⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 9, 2026Neurology

Serum NfL Z-score as a Biomarker of Disease Severity and Treatment History in the Largest CIDP Cohort to Date: Insights from the ADHERE Trial (P7-9.004)

L. Querol Roger Collet Vidiella Marta Caballero‐Ávila Tineke Casneuf Erik Hofman Geoffrey Istas Paula Llarch L. Aguilar Elba Pascual‐Goñi Jason Waddell Bianca Balbino

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate neurofilament light chain (NfL) as a biomarker for assessing disease severity and treatment history in CIDP.
Utilized serum NfL Z-score measurements
Analyzed data from the largest cohort of CIDP to date
Employed findings from the ADHERE Trial
Higher NfL Z-scores correlate with increased disease severity
NfL levels provide insights into treatment efficacy
Identified significant associations between NfL and patient outcomes

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

To measure neurofilament light chain (NfL) as a biomarker in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Querol et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf393faef96ed7f05603f https://doi.org/10.1212/wnl.0000000000216816

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Neurofilament Light Chain Levels in a Large Idiopathic Peripheral Neuropathy Cohort2025 · 4 citations
2Serum neurofilament light chain associates with symptom burden in Lyme neuroborreliosis patients: a longitudinal cohort study from Norway2024 · 7 citations
3Neurofilament light: a narrative review on biomarker utilityreview · 2021 · 53 citations
4Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosisCohort Study · 2020 · 162 citations
5Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disordersCohort Study · 2020 · 108 citations
6Serum neurofilament light protein as a biomarker across the cognitive decline continuum: a cross-sectional study from an Indian cohortCross-Sectional Study · 2026
7Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management2024 · 203 citations
8Neurofilament light chain as a prognostic marker in cerebral adrenoleukodystrophy2025 · 1 citations
9Pearls & Oy-sters: Trace Visualization of the Central Retinal ArteryNeurology · 2026
10Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathologyNeurology · 2016

More from Neurology

More from Universitat Autònoma de Barcelona

More from Hospital de Sant Pau

More from Argenx (Belgium)